SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-21-000079
Filing Date
2021-11-10
Accepted
2021-11-10 16:34:26
Documents
42
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q awh-20210930x10q.htm   iXBRL 10-Q 2298198
2 EX-31.1 awh-20210930xex31_1.htm EX-31.1 15001
3 EX-31.2 awh-20210930xex31_2.htm EX-31.2 16353
4 EX-32.1 awh-20210930xex32_1.htm EX-32.1 12323
  Complete submission text file 0000926617-21-000079.txt   6556632

Data Files

Seq Description Document Type Size
5 EX-101.SCH awh-20210930.xsd EX-101.SCH 29843
6 EX-101.CAL awh-20210930_cal.xml EX-101.CAL 43029
7 EX-101.DEF awh-20210930_def.xml EX-101.DEF 128421
8 EX-101.LAB awh-20210930_lab.xml EX-101.LAB 260847
9 EX-101.PRE awh-20210930_pre.xml EX-101.PRE 231563
10 EXTRACTED XBRL INSTANCE DOCUMENT awh-20210930x10q_htm.xml XML 1202678
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 211397233
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences